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Abstract
Aims—To determine whether the CHA2DS2-VASc score can predict adverse outcomes such as 
death, ischemic stroke, and major hemorrhage, in patients with systolic heart failure in sinus 
rhythm.
Methods and Results—CHA2DS2-VASc scores were calculated for 1,101 patients randomized 
to warfarin and 1,123 patients randomized to aspirin. Adverse outcomes were defined as death or 
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ischemic stroke, death alone, ischemic stroke alone, and major hemorrhage. Using proportional 
hazards models, we found that each 1-point increase in the CHA2DS2-VASc score was associated 
with increased hazard of death or ischemic stroke events (hazard ratio [HR] for the warfarin arm = 
1.21 [1.13–1.30], p<0.001; for aspirin, HR = 1.20 [1.11–1.29], p<0.001). Similar increased 
hazards for higher CHA2DS2-VASc scores were observed for death alone, ischemic stroke alone, 
and major hemorrhage. Overall performance of the CHA2DS2-VASc score was assessed using c-
statistics for full models containing the risk score, treatment assignment, and score-treatment 
interaction, with the c-statistics for the full models ranging from 0.57 for death to 0.68 for major 
hemorrhage.
Conclusions—The CHA2DS2-VASc score predicted adverse outcomes in patients with systolic 
HF in sinus rhythm, with modest prediction accuracy.
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Background
Patients with heart failure with reduced ejection fraction (HFrEF) are at increased risk for 
adverse outcomes, including death and stroke.(1, 2) For patients with HFrEF in sinus 
rhythm, there has been recent interest in assessing whether the risk of these adverse 
outcomes can be accurately predicted by existing risk scores that incorporate established risk 
factors.(3–5) In particular, although the CHA2DS2-VASc risk score (incorporating risk 
factors including congestive heart failure, hypertension, age ≥75 years [2 points], age 65–75 
years, diabetes, stroke/transient ischemic attack/thromboembolism [2 points], vascular 
disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], and female 
sex) was developed for patients with atrial fibrillation,(6) Melgaard and colleagues recently 
described its use for predicting the risk of death and stroke in HFrEF patients in sinus 
rhythm.(3) We therefore undertook this analysis of patients enrolled in the Warfarin versus 
Aspirin in Reduced Cardiac Ejection Fraction Trial (WARCEF),(7) to evaluate whether the 
CHA2DS2-VASc risk score can predict death, ischemic stroke, and major hemorrhage in 
patients with HFrEF in sinus rhythm who received warfarin or aspirin.
Methods
The protocol for the randomized, double blinded WARCEF trial (http://
www.ClinicalTrials.gov No. NCT00041938) has been described previously.(7, 8) Briefly, 
patients with left ventricular ejection fraction (LVEF) ≤35% and who were in SR were 
randomized to receive warfarin or aspirin. Additional eligibility criteria included age ≥18 
years old, having no contraindications to warfarin, having a modified Rankin score of 4 or 
less, and on evidence-based heart failure medications (beta-blocker, angiotensin-converting-
enzyme inhibitor or angiotensin-receptor blocker, or hydralazine and nitrates). Patients were 
excluded if they had a clear indication for warfarin or aspirin, or if they had a condition that 
conferred a high risk of cardiac embolism. A total of 2,305 participants were recruited from 
168 centers in 11 countries from October 2002 to January 2010. The investigation conforms 
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with the principles outlined in the Declaration of Helsinki.(9) All subjects provided 
informed consent.
For the WARCEF trial, ischemic stroke was defined as a clinically relevant new lesion 
detected on computed tomography or magnetic resonance imaging or, in the absence of a 
new lesion, clinical findings that were consistent with the occurrence of clinical stroke and 
that lasted for longer than 24 hours. Major bleeding was defined as intracerebral, epidural, 
subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding 
causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or 
bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical 
intervention. A blinded independent end-point adjudication committee adjudicated all stroke 
and major bleeding events.
For each participant, the CHA2DS2-VASc risk score was calculated based on the approach 
described by Lip and colleagues.(6) For this analysis, 81 participants were excluded because 
incomplete data precluded the calculation of the CHA2DS2-VASc score. Because stroke and 
bleeding risk are expected to differ for patients receiving warfarin and aspirin, we performed 
all analyses separately for the warfarin and aspirin arms of the WARCEF trial on an intent-
to-treat (ITT) basis. Baseline characteristics of the study participants were compared by 
treatment group using two-sample t-test for continuous variables and Chi-squared test 
categorical variables. For each CHA2DS2-VASc score, we calculated incidence rate per 100 
patient-years for the composite outcome of death and ischemic stroke, as well as for the 
individual outcomes of death, ischemic stroke, and major bleeding. Exact Poisson 95% 
confidence intervals of the incidence rates were provided. To determine the association 
between CHA2DS2-VASc score and each outcome above, as well as to investigate whether 
the CHA2DS2-VASc score influenced the treatment effect of warfarin versus aspirin, we 
constructed Cox proportional hazard models that incorporated treatment assignment, the 
CHA2DS2-VASc score, and their interaction term. Model discrimination was assessed using 
Harell’s c-index. Model calibration was assessed using the survival-adapted Hosmer-
Lemeshow χ2 goodness of fit test.(10) The test statistic measures the difference between the 
predicted and the observed probabilities of risk. A small p-value suggests that the model is 
not well calibrated. P-values of <0.05 were considered statistically significant for all testing. 
All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
Results
For this analysis, a total of 2,204 participants were included, of whom 1,101 were enrolled 
in the warfarin arm and 1,123 were enrolled in the aspirin arm. The mean (SD) age of 
participants were 60.8 (11.3) years old, and 435 (19.6%) were female. Baseline 
characteristics of WARCEF participants by treatment arm are described in Table 1.
Because all WARCEF participants had a diagnosis of heart failure, the minimum CHA2DS2-
VASc score was 1; the maximum was 9. The composite outcome of death and ischemic 
stroke occurred in 588 (27%) of the 2,204 participants; the risk significantly increased with 
each 1-point increase in CHA2DS2-VASc score (Figure) for participants enrolled in both 
warfarin (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.13–1.30, p<0.001) and 
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aspirin arms (HR 1.20, 95% CI 1.11–1.29, p<0.001). Similar trends were observed for the 
individual outcomes of ischemic stroke (Table 2), death alone and major hemorrhage (Table 
3). For ischemic stroke, the incidence rate per 100 patient-years was largely above 1% for 
CHA2DS2-VASc scores of 5 and above for patients receiving warfarin, and for CHA2DS2-
VASc scores of 2 and above for patients receiving aspirin.
The treatment effect of warfarin versus aspirin did not significantly differ according to the 
CHA2DS2-VASc score for all outcomes examined. Model discrimination was modest for the 
composite outcome of death and ischemic stroke (c-index 0.58, 95% CI 0.56–0.60) and the 
individual outcome of death (c-index 0.57, 95% CI 0.55–0.60), but was higher for ischemic 
stroke (c-index 0.64, 95% CI 0.57–0.70) and for major hemorrhage (c-index 0.68, 95% CI 
0.62–0.73) (Tables 2 and 3). The survival-adapted Hosmer-Lemeshow goodness-of-fit test p-
values were larger than 0.05 for all outcomes, suggesting that none of the models had a 
significant lack of fit.
Discussion
In this retrospective analysis of the WARCEF trial, we found that in patients with heart 
failure in sinus rhythm, the CHA2DS2-VASc score was moderately predictive of adverse 
outcomes, including death or ischemic stroke, and the individual outcomes of death, 
ischemic stroke, and major hemorrhage. Increased CHA2DS2-VASc risk score was 
consistently associated with increased stroke risk for both the aspirin and warfarin arms of 
the WARCEF cohort. There was no significant interaction between treatment assignment 
and the CHA2DS2-VASc score for these outcomes.
Our results are largely consistent with those reported by Melgaard and colleagues, who 
found that the CHA2DS2-VASc score predicted death, ischemic stroke, and 
thromboembolism, in a nationwide cohort of 33,592 heart failure patients with reduced or 
preserved ejection fraction without concurrent atrial fibrillation.(3) In that study, the c-
statistics for the CHA2DS2-VASc ranged from 0.63 to 0.69 for the individual outcomes. 
These values are slightly higher than those in our analysis. However, at each level of the 
CHA2DS2-VASc score, the absolute risk for ischemic strokes was higher in the Danish 
cohort, ranging from 1.5% per year for a score of 1 to 7% for a score of 6, where as across 
the same range of CHA2DS2-VASc scores in the WARCEF cohort the stroke risk was 0.3% 
to 1.1% in the aspirin arm and 0.4% to 1.1% in the warfarin arm. Potential reasons for this 
include the protective effects of aspirin and warfarin, inclusion of younger patients in 
WARCEF, and statistical imprecision due to the sample size. Regardless of the reason, these 
differences suggest additional analyses of independent cohorts are needed to better calibrate 
how the CHA2DS2-VASc score can predict stroke risk in heart failure patients in sinus 
rhythm, especially as the threshold for benefit from initiating anticoagulation is commonly 
thought to be a stroke risk of between 1–2%.(11, 12)
In addition to the CHA2DS2-VASc score, other approaches to risk stratification for heart 
failure patients in sinus rhythm have been examined recently. Abdul-Rahim and colleagues 
have found that in in patients with heart failure with reduced ejection fraction who are in 
sinus rhythm, risk scores that included clinical risk factors (age, New York Heart 
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Association class, diabetes treated with insulin, body mass index, previous stroke) and N-
terminal pro B-type natriuretic peptide accurately predicted strokes.(4) Similarly, we have 
previously demonstrated that major bleeding in WARCEF participants could be predicted by 
existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, 
Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol 
Concomitantly (HAS-BLED) score and the Outpatient Bleeding Risk Index (OBRI).(5) 
Taken together, these findings all suggest that risk prediction in heart failure patients in sinus 
rhythm can be further refined. Although current guidelines do not recommend routine 
anticoagulation in this patient population,(13, 14) ongoing studies, such as the 
COMMANDER-HF randomized, controlled trial, are assessing the potential benefit of 
newer oral anticoagulants such as rivaroxaban.(15) Given the superior safety profile of these 
agents compared with warfarin, improved risk stratification of heart failure patients in sinus 
rhythm, especially with regards to stroke and bleeding risk,(16, 17) will greatly aid the 
identification of patients who may benefit from such therapy.(11)
The limitations of our analysis include its retrospective design and the modest number of 
stroke events. As mentioned previously, since WARCEF was a randomized, controlled trial, 
it is possible that healthier patients were selected, which could lead to underestimation of 
stroke risk and affect the generalizability of our findings. Similarly, since all patients in 
WARCEF received either warfarin or aspirin, the true stroke risk of heart failure patients in 
sinus rhythm who are not on anticoagulant therapy may be higher than described here. We 
did not construct a model including hemodynamic or laboratory parameters using WARCEF 
participants, and it is possible such a model may be superior to the CHA2DS2-VASc risk 
score. However, any such model would also need to be validated externally, while the 
CHA2DS2-VASc risk score is easy to calculate and already widely accepted, making it more 
likely to be clinically useful should future studies continue to confirm our findings. Finally, 
we did not formally monitor for the occurrence of asymptomatic atrial fibrillation during the 
WARCEF study, although a small number of participants (~10%) did develop clinical atrial 
fibrillation during the follow-up period.(18) Although this may have contributed to the 
relationship between the CHA2DS2-VASc score and clinical outcomes observed in our 
analysis, this does not change our finding that the CHA2DS2-VASc score represents a 
potentially useful tool for risk stratification in this patient population.
Despite these limitations, our findings are timely additions to the literature on understanding 
stroke risk in heart failure patients in sinus rhythm. Our analysis confirms that the 
CHA2DS2-VASc score can predict stroke risk in this population, and can potentially inform 
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Adverse outcomes by CHA2DS2-VASc score.
Incidence rate of ischemic stroke (top panel), and death or ischemic stroke (bottom panel), 
by categories of CHA2DS2-VASc score. Because only 1 patient had a CHA2DS2-VASc 
score of 9, data are not shown for that category.
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Table 1
Baseline characteristics of the study participants, according to treatment group (warfarin versus aspirin). For 
continuous variables, mean ± SD were reported, and p-values were calculated using two-sample t-test. For 
categorical variables, number /total number (%) were reported, and p-values were calculated using Chi-
squared test.
Characteristic Warfarin (n=1101) Aspirin (n=1123) p-value
Age - years 60.9± 11.5 60.7±11.1 0.647
Male sex 879/1101 (79.8) 910/1123 (81.0) 0.477
Race or ethnic group 0.862
  Non-Hispanic white 830/1101 (75.4) 856/1123 (76.2) .
  Non-Hispanic black 158/1101 (14.4) 153/1123 (13.6) .
  Hispanic 83/1101 (7.5) 79/1123 (7.0) .
  Other 30/1101 (2.7) 35/1123 (3.1) .
Body-mass index – kg / m2 28.9± 5.9 29.2± 6.0 0.197
Systolic blood pressure - mmHg 124.0±19.4 124.2±18.4 0.832
Diastolic blood pressure - mmHg 74.1±11.6 74.5±11.3 0.402
Pulse - beats/min 71.8±11.3 72.1±12.5 0.479
Hypertension 669/1101 (60.8) 692/1123 (61.6) 0.678
Diabetes Mellitus 359/1101 (32.6) 337/1123 (30.0) 0.187
Atrial Fibrillation 42/1101 (3.8) 38/1123 (3.4) 0.585
Peripheral Vascular Disease 130/1101 (11.8) 122/1123 (10.9) 0.483
Prior stroke or TIA 148/1101 (13.4) 137/1123 (12.2) 0.381
Ischemic Cardiomyopathy 475/1101 (43.1) 488/1123 (43.5) 0.882
Smoking status 0.424
  Current smoker 211/1099 (19.2) 193/1122 (17.2) .
  Former smoker 563/1099 (51.2) 579/1122 (51.6) .
  Never smoked 325/1099 (29.6) 350/1122 (31.2) .
NYHA classification 0.502
  1 145/1098 (13.2) 160/1118 (14.3) .
  2 595/1098 (54.2) 626/1118 (56.0) .
  3 343/1098 (31.2) 319/1118 (28.5) .
  4 15/1098 (1.4) 13/1118 (1.2) .
Ejection fraction - % 24.6± 7.5 24.9± 7.5 0.319
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Table 2
Incidence rate per 100 patient-years for death or ischemic stroke and ischemic stroke only, by categories of 
CHA2DS2-VASc score. Hazard ratios are for each 1-point increase in CHA2DS2-VASc score, using models 
that contained treatment assignment, CHA2DS2-VASc score and their interaction.
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Table 3
Incidence rate per 100 patient-years for death and major hemorrhage, by categories of CHA2DS2-VASc score. 
Hazard ratios are for each 1-point increase in CHA2DS2-VASc score, using models that contained treatment 
assignment, CHA2DS2-VASc score and their interaction.
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